Product Browser

Last updated: 2023/3/19

Product Compare

Product Compare Cancel Click this icon to add products to compare list. Select up to 10 products.

Quick Order (Tutorial)

Input Catalog #,
place order here!
Catalog # :
  • Where to buy
  • Choose your location
Bulk order
Custom Services
2019 Next Day Shipping

COVID-19 Gamma Variant Pseudovirus Neutralizing Antibody Assay (Luciferase) Coronavirus

  • Catalog # : DE0008
  • Visit Frequency :
  • Countries :
  • Specification
  • Product Description:
  • COVID-19 Gamma Variant Pseudovirus Neutralizing Antibody Assay (Luciferase) provides a highly sensitive and quantitative measurement of neutralizing antibodies.
  • Storage Instruction:
  • 293T-hACE2 cell Store at liquid nitrogen.
    Pseudovirus Store at -80°C.
    Aliquot to avoid repeated freezing and thawing.
  • Supplied Product:
  • Kit content:
    1 kit is sufficient for 100 assays in 24 well plates
    1. 293T-hACE2 cell, 2x106cells/vial, FBS with 10% DMSO
    2. SARS-CoV-2 Gamma Variant Pseudovirus Expressing Luciferase
  • Materials Required But NOT Supplied:
  • 1. SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova
    2. ZymeFree™ Enzyme Free Cell Dissociation Reagent,
     Cat# TCL028-100ML, HIMEDIA
    3. DMEM culture medium containing 10% FBS (complete medium)
    4. Luciferase Assay System, Cat# E1500, Promega
     a. Luciferase Assay Substrate (lyophilized)
     b. Luciferase Assay Buffer
     c. Luciferase Cell Culture Lysis Reagent, 5X
    5. TC-Treated 24 Well Plates, Cat# 3524, Corning
    6. OptiPlate™-96, Cat# 6005290, PerkinElmer
  • Variant:
  • B.1.1.28.1, P.1
  • Suitable Sample:
  • 1. Immunized Serum
    2. Infected Serum
    3. Neutralizing Antibodies
    4. Peptide Inhibitors or Proteins
    5. Compounds Targeting Spike Induced Cell Fusion
  • Sample Volume:
  • 10-50 uL (please check sample source)
  • Detection Method:
  • Luciferase Activity
  • Regulatory Status:
  • For research use only (RUO)
  • Applications
  • Neutralization
  • Neutralization
  • RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).
  • Neutralization
  • Neutralization
  • SARS-CoV-2 gamma variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7 and LALAPG 7F7, and then added into 293T-ACE cells.
  • In vivo Neutralization
  • <i>In vivo</i> Neutralization
  • Hamsters received 2 doses of humanized monoclonal antibody 7F7 and then were infected with SARS-CoV-2 Gamma Variant Pseudovirus Expressing Luciferase (Cat # U0408).
  • Application Image
  • RSS
  • YouTube
  • Linkedin
  • Facebook